Accuron MedTech, a division of Accuron Technologies Limited, a wholly-owned subsidiary of Temasek Holdings, has led an investment totalling $11.2 million into AWAK Technologies, a Singapore medtech start-up developing solutions that address end-stage renal disease.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
